Inhibrx Biosciences Inc. (INBX) Financial Ratios & Valuation Metrics Analysis - P/E, ROE, Debt Ratios & Profitability - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Inhibrx Biosciences Inc.

    NASDAQ: INBX · Real-Time Price · USD
    35.65
    0.59 (1.67%)
    At close: Oct 03, 2025, 3:59 PM
    36.36
    1.99%
    After-hours: Oct 03, 2025, 06:58 PM EDT

    Inhibrx Biosciences Ratios and Metrics

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    PE Ratio
    		 0.13 -7.42 -6.8 -20.3
    PEG Ratio
    		 -0.00 -0.18 -0.1 0.72
    PS Ratio
    		 1.11K 994.97 450.85 232.97
    PB Ratio
    		 1.67 41.17 17.02 31.69
    P/FCF Ratio
    		 -1.13 -9.05 -8.52 -20.45
    P/OCF Ratio
    		 -1.15 -9.26 -8.57 -20.67
    OCF/S Ratio
    		 -972.04 -107.39 -52.6 -11.27
    Debt / Equity Ratio
    		 0.06 4.83 3.57 1.35
    Quick Ratio
    		 3.94 5.25 10.18 6.23
    Current Ratio
    		 3.94 5.25 10.17 6.20
    Asset Turnover
    		 0.00 0.01 0.01 0.05
    Interest Coverage
    		 -24.57 -6.89 -8.02 -14.68
    Return on Equity
    		 12.63 -5.55 -2.5 -1.56
    Return on Assets
    		 9.34 -0.78 -0.5 -0.54
    Return on Invested Capital
    		 -2.34 -0.86 -0.48 -0.59
    Dividend Yield
    		 0.06 n/a n/a n/a
    Payout Ratio
    		 0.01 n/a n/a n/a
    Gross Profit Margin
    		 -10.43 0.34 -49.27 0.62
    Net Profit Margin
    		 8.44K -134.09 -66.25 -11.48
    Pretax Profit Margin
    		 8.44K -133.18 -66.25 -11.48
    Operating Profit Margin
    		 -1.66K -121.79 -58.9 -10.75
    FCF Margin
    		 -985.03 -109.95 -52.91 -11.39
    EBITDA Margin
    		 8.52K -114.83 -57.4 -10.58

    Add to Watchlist